As more pharmaceutical businesses focus on creating innovative, targeted therapies, the industry is having to adapt like never before. Contamination control in particular has advanced and developed significantly.
Global product manager, Michael Avraam, discusses how businesses are transforming their approaches to containment and the safe development of pharmaceutical products in an article for Pharmaceutical Manufacturing.
Ensuring a safe and sterile environment for active pharmaceutical ingredients (APIs) and formulation ingredients is fundamental during aseptic processing. Air filtration systems, materials transfer and of course operators themselves bring an abundance of potential hazards during the manufacturing process. Therefore there have been many techniques developed in order to provide a risk-averse and contamination-free environment for production.
ChargePoint Technology's global product manager, Christian Dunne discusses the various techniques available with Pharmaceutical Manufacturing. From barrier technologies such as isolators and RABS to split butterfly valve technology (SBV), Christian weighs up the benefits of each and their place within the sector. You can read the full article here
As the demand for high potency drug handling continues to rise, as does the need for high containment facilities. However, currently many manufacturing facilities are unable to manage the upsurge and are needing to upgrade, develop and sometimes even construct new facilities to handle the significant demand. Under these circumstances it is more important than ever for companies to select the right partners with specialist containment solutions so they can adapt to the industry changes and containment challenges ahead.
Our very own Michael Avraam discusses the risks, challenges and innovative steps now being taken in today's high potency sector with CPhI Online. You can read the full Q&A here.
As 2018 gets into full swing, we enter into discussions with other pharmaceutical industry experts in European Pharmaceutical Manufacturer...
Looking back at 2017...
As the year draws to a close, we have reached a natural point of reflection here at ChargePoint. 2017 has been yet another significant year for the pharmaceutical industry, which is experiencing a notable period of change. The last few years have seen the industry begin to transform; with the growing use of data and technology, increasing development of high potency products, the enforcement of serilisation regulations in the US, and an ever increasing move towards single-use technology. Importantly for ChargePoint, the biopharma boom continues and therefore the demand for containment, particularly from therapeutic areas such as oncology and hormonal drug products, continues to grow.